506 related articles for article (PubMed ID: 36687125)
1. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis.
Tovo CV; de Mattos AZ; Coral GP; Sartori GDP; Nogueira LV; Both GT; Villela-Nogueira CA; de Mattos AA
World J Gastroenterol; 2023 Jan; 29(2):343-356. PubMed ID: 36687125
[TBL] [Abstract][Full Text] [Related]
2. A risk prediction model for hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis: HCC prediction for non-cirrhotic NAFLD.
Kim GA; Park Y; Oh SJ; Jung J; Han S; Chang HS; Park SW; Kim TH; Park HW; Choe J; Kim J; Lee HC
Liver Int; 2024 Mar; 44(3):738-748. PubMed ID: 38110797
[TBL] [Abstract][Full Text] [Related]
3. Clinical features and management issues of NAFLD-related HCC: what we know so far.
Pugliese N; Alfarone L; Arcari I; Giugliano S; Parigi TL; Rescigno M; Lleo A; Aghemo A
Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):31-43. PubMed ID: 36576057
[TBL] [Abstract][Full Text] [Related]
4. Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis.
Behari J; Gougol A; Wang R; Luu HN; Paragomi P; Yu YC; Molinari M; Chopra K; Malik SM; Geller D; Yuan JM
Hepatol Commun; 2023 Jul; 7(7):. PubMed ID: 37395730
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease.
Seif El Dahan K; Daher D; Singal AG
Clin Mol Hepatol; 2023 Feb; 29(Suppl):S207-S219. PubMed ID: 36103899
[TBL] [Abstract][Full Text] [Related]
6. Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study.
Huang DQ; Tran S; Barnett S; Zou B; Yeo YH; Cheung R; Nguyen MH
Hepatol Int; 2024 Apr; 18(2):540-549. PubMed ID: 38079023
[TBL] [Abstract][Full Text] [Related]
7. Non-alcoholic fatty liver disease: Definition and subtypes.
Han SK; Baik SK; Kim MY
Clin Mol Hepatol; 2023 Feb; 29(suppl):S5-S16. PubMed ID: 36577427
[TBL] [Abstract][Full Text] [Related]
8. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Cernea S; Onișor D
World J Gastroenterol; 2023 Jan; 29(2):286-309. PubMed ID: 36687124
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study.
Grecian SM; McLachlan S; Fallowfield JA; Kearns PKA; Hayes PC; Guha NI; Morling JR; Glancy S; Williamson RM; Reynolds RM; Frier BM; Zammitt NN; Price JF; Strachan MWJ
Liver Int; 2020 Sep; 40(9):2252-2262. PubMed ID: 32638496
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy.
Polyzos SA; Chrysavgis L; Vachliotis ID; Chartampilas E; Cholongitas E
Semin Cancer Biol; 2023 Aug; 93():20-35. PubMed ID: 37149203
[TBL] [Abstract][Full Text] [Related]
12. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment.
Margini C; Dufour JF
Liver Int; 2016 Mar; 36(3):317-24. PubMed ID: 26601627
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
14. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
[TBL] [Abstract][Full Text] [Related]
15. NAFLD-related hepatocellular carcinoma: The growing challenge.
Shah PA; Patil R; Harrison SA
Hepatology; 2023 Jan; 77(1):323-338. PubMed ID: 35478412
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and risk-stratification of NAFLD-associated HCC.
Ioannou GN
J Hepatol; 2021 Dec; 75(6):1476-1484. PubMed ID: 34453963
[TBL] [Abstract][Full Text] [Related]
17. Rational HCC screening approaches for patients with NAFLD.
Singal AG; El-Serag HB
J Hepatol; 2022 Jan; 76(1):195-201. PubMed ID: 34508791
[TBL] [Abstract][Full Text] [Related]
18. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.
Stine JG; Wentworth BJ; Zimmet A; Rinella ME; Loomba R; Caldwell SH; Argo CK
Aliment Pharmacol Ther; 2018 Oct; 48(7):696-703. PubMed ID: 30136293
[TBL] [Abstract][Full Text] [Related]
19. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
Bertot LC; Adams LA
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
[TBL] [Abstract][Full Text] [Related]
20. RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE.
Cavalcante LN; Dezan MGF; Paz CLDSL; Lyra AC
Arq Gastroenterol; 2022; 59(4):540-548. PubMed ID: 36515349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
